Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.

Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K.

EBioMedicine. 2017 Feb;16:41-50. doi: 10.1016/j.ebiom.2017.01.042. Epub 2017 Jan 31. Review.


Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells.

Korsen M, Bragado Alonso S, Peix L, Bröker BM, Dressel A.

PLoS One. 2015 Jun 18;10(6):e0129182. doi: 10.1371/journal.pone.0129182. eCollection 2015.


Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.

Thöne J, Ellrichmann G.

Drug Healthc Patient Saf. 2013;5:37-47. doi: 10.2147/DHPS.S28822. Epub 2013 Feb 26.


Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine.

Schreiner TL, Miravalle A.

J Cent Nerv Syst Dis. 2012 Jan 3;4:1-14. doi: 10.4137/JCNSD.S5128. Print 2012.


Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.

Murphy JA, Harris JA, Crannage AJ.

Neuropsychiatr Dis Treat. 2010 Oct 5;6:619-25. doi: 10.2147/NDT.S3501.


Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.

Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC.

Drug Des Devel Ther. 2010 Jul 21;4:117-26. Review.

Supplemental Content

Loading ...
Support Center